MarketBeat
24 Oct 2026, 22:02 UTC · 2h ago
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial
Impact · against what's priced in
The Phase 3 melanoma results are largely a confirmation of the bullish outlook already embedded in Moderna's price, though the high manufacturing success rate provides critical operational validation. For Merck, the results move the mRNA vaccine from a discounted possibility toward a tangible driver for Keytruda's lifecycle extension.
- MRK+0.40
Challenges what's priced in
- The price assumes
The full upside of the mRNA cancer vaccine (Intismeran) with Keytruda across multiple tumor types
The price previously declined to pay for the mRNA vaccine upside; a 42% reduction in melanoma recurrence provides the clinical evidence needed to start pricing in the bull case for Keytruda's expanded utility.
What MRK's price assumes · Sep 11
